Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor and does not bind appreciably to the other murine EP receptors or the DP, TP, FP, and IP receptors. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Butaprost effectively reduces the subconjunctival scarring response. Given the significance of wound healing modulation in blebs, butaprost's inhibitory effect on subconjunctival Tenon's fibroblasts may be beneficial in managing postoperative scarring in glaucoma surgery.

Nicocodine is an opioid related to codeine. It is also an antitussive agent. Nicocodine exhibits at least twice the potency of codeine in clinical experiments. The study of the pharmacokinetic behaviour of nicocodine by means of blood and brain level curves of rats after i .v. application showed that the penetration of the blood brain barrier seems to be favoured for nicocodine. The detected peak concentration of nicocodine in brain after i.v. application is 4.4 times higher than the blood level values at the same time - codeine the main metabolite is detected in almost equal amounts in brain and blood. A comparative assay of codeine and nicocodine after p.o. application of equimolar doses per kg body weight revealed that predominantly codeine is found in brain and its peak value after nicocodine administration is 3-fold higher than after codeine administration. Nicocodine is hydrolysable to morphine and the WHO Expert Committee on Addiction-Producing Drugs (1962) recommended its international control as a narcotic, like other convertible drugs in the morphine series.

FLUFOSAL is an antithrombotic agent.

Drobuline is a potent cardiac depressant (anti-arrhythmic) agent, which has been found to be effective against ventricular arrhythmias in dogs. This compound is a racemic mixture having a single center of optical activity. The two isomers of drobuline were found to be equally potent in converting cardiac arrhythmias in dogs after intravenous administration. The major route of biotransformation of drobuline in the dog was shown to be conjugation with glucuronic acid.

Oxabrexine was developed as a diuretic; however, this compound has never been marketed. Information about the current use of this compound is not available.

Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.

Etiocholanone is an androstane neurosteroid. Etiocholanone potentiates GABA-A receptor currents and exerts anticolvunsant properties in rodents. Etiocholanolone demostrates pyrogenic properties.

Demecycline is a tetracycline antibiotic drug. Tetracyclines have a broad spectrum of anti-microbial activity and act by interfering with bacterial protein synthesis. Demecycline is used to treat a wide range of infections caused by bacteria. Some of these infections are: Severe acne; Infections of the brain and liver caused by the bacteria Leptospira; Infection caused by Brucella bacteria (brucellosis); Infections caused by Rickettsiae micro-organisms transmitted by lice, fleas, ticks and mites; Infections of the sex organs and organs associated with urination (genito-urinary infections) such as an infection called chancroid, non-gonococcal urethritis; Rare infections such as Tularaemia and bubonic plague. The following undesirable effects have been reported for demecycline: loss of appetite, nausea, vomiting, diarrhea, inflammation of the tongue, difficulty in swallowing, intestinal inflammation, and inflammatory lesions, rashes, redness of the skin, pigmentation, sensitivity to light, acute kidney failure and others.

Pregnanediol is a chief steroid metabolite of progesterone that is biologically inactive and occurs as pregnanediol glucuronate in the urine. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. A test can be done to measure the amount of pregnanediol in urine. The urine test offers an indirect way to measure progesterone levels in the body. It is a standard in the colorimetric determination of urinary pregnanediol in clinical laboratories.